Advertisement
UK markets close in 2 hours 49 minutes
  • FTSE 100

    7,959.65
    +27.67 (+0.35%)
     
  • FTSE 250

    19,871.23
    +60.57 (+0.31%)
     
  • AIM

    743.23
    +1.12 (+0.15%)
     
  • GBP/EUR

    1.1692
    +0.0023 (+0.20%)
     
  • GBP/USD

    1.2633
    -0.0005 (-0.04%)
     
  • Bitcoin GBP

    56,012.84
    -177.75 (-0.32%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,250.06
    +1.57 (+0.03%)
     
  • DOW

    39,786.59
    +26.51 (+0.07%)
     
  • CRUDE OIL

    82.52
    +1.17 (+1.44%)
     
  • GOLD FUTURES

    2,229.40
    +16.70 (+0.75%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • HANG SENG

    16,541.42
    +148.58 (+0.91%)
     
  • DAX

    18,491.35
    +14.26 (+0.08%)
     
  • CAC 40

    8,223.07
    +18.26 (+0.22%)
     

BUZZ-GSK partner Adaptimmune jumps on good cell therapy data

** Adaptimmune up 30 percent on news that second solid tumour type responds to its cell therapy, boosting hopes for biotech company's NY-ESO SPEAR T-cells partnered with GlaxoSmithKline (Other OTC: GLAXF - news)

** Adaptimmune reports three partial responses (two confirmed and one to be confirmed) and one case of stable disease in the first four patients dosed in myxoid/round cell liposarcoma trial

** GSK licensed rights to NY-ESO cell therapy in September 2017 and UK drugmaker sees product as important part of its drive to rebuild oncology R&D. GSK shares up 0.6 percent

** Adaptimmune founded to exploit cell therapy technology originally developed at Oxford University and firm listed on Nasdaq (Frankfurt: 813516 - news) in 2015